Skip to main content

Table 3 RH of clinical progression from fitting a Cox regression model, according to the 33% percentiles of the distribution of hs-CRP

From: Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV

  Relative hazards of AIDS/SNAE/death
hs-CRP, mg/L Unadjusted RH (95% CI) p-value Adjusteda RH (95% CI) p-value Adjustedb RH (95% CI) p-value
All patients (n = 375)
 0.0–1.1 1   1   1 Global
       0.002
 1.2–5.3 1.42 (0.88, 2.27) 0.147 1.50 (0.89, 2.52) 0.127 1.61 (0.95, 2.73) 0.078
 5.4+ 1.85 (1.09, 3.15) 0.023 1.59 (0.88, 2.89) 0.128 1.69 (0.92, 3.11) 0.093
 per natural log higher 1.12 (0.99, 1.27) 0.065 1.06 (0.89, 1.25) 0.539 1.12 (0.93, 1.36) 0.238
Complete case analysisc (n = 208)
 0.0–1.1 1   1   1 Global
       0.07
 1.2–5.3 1.15 (0.60, 2.20) 0.674 1.39 (0.66, 2.91) 0.386 1.70 (0.77, 3.76) 0.189
 5.4+ 1.43 (0.67, 3.06) 0.352 1.01 (0.41, 2.51) 0.982 1.29 (0.49, 3.42) 0.608
 per natural log higher 1.11 (0.93, 1.32) 0.242 1.06 (0.89, 1.25) 0.539 1.12 (0.93, 1.36) 0.238
Restricting to people with hs-CRP lower than 10 mg/L (n = 335)
 0.0–1.1 1   1   1 Global
       0.002
 1.2–5.3 1.40 (0.88, 2.25) 0.158 1.56 (0.92, 2.64) 0.098 1.78 (1.05, 3.04) 0.034
 5.4+ 1.28 (0.59, 2.79) 0.535 1.42 (0.57, 3.49) 0.451 1.42 (0.57, 3.56) 0.453
 per natural log higher 1.02 (0.87, 1.21) 0.779 1.08 (0.84, 1.39) 0.562 1.12 (0.86, 1.47) 0.405
  1. aadjusted forage, CD4, VL, HCV/HBV, year of cART, duration of HIV infection at starting cART,type of cART started as well as all other biomarkers
  2. badjusted forage, mode of HIV transmission, alcohol consumption, smoking, CD4, VL, HCV/HBV, year of cART, duration of HIV infection at starting cART,type of cART started as well as all other biomarkers
  3. ccomplete data for all four biomarkers